indomethacin has been researched along with Acute Confusional Senile Dementia in 43 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase as the global population ages." | 5.62 | Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents. ( Huang, W; Huang, Y; Ma, L; Wang, R; Yang, G, 2021) |
| "A 92-year-old white man with a history of senile dementia of the Alzheimer type, glaucoma, and constipation was treated with indomethacin for an episode of pseudogout." | 3.70 | Indomethacin-induced behavioral changes in an elderly patient with dementia. ( Kuyumjian, J; Mallet, L, 1998) |
| " Compared to indomethacin, the favored safety profile and equal efficacy of DP-155 establish the compound as a potential candidate for chronic use to treat AD-related pathology and for analgesia." | 2.44 | DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. ( Dahan, A; Duvdevani, R; Dvir, E; Elman, A; Friedman, JE; Hoffman, A; Shapiro, I; Simmons, D, 2007) |
| " Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset." | 2.43 | Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. ( Praticò, D; Townsend, KP, 2005) |
| "Late-onset sporadic Alzheimer's disease is a heterogeneous disorder." | 2.42 | Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. ( Casserly, I; Topol, E, 2004) |
| "Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase as the global population ages." | 1.62 | Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents. ( Huang, W; Huang, Y; Ma, L; Wang, R; Yang, G, 2021) |
| "To evaluate their potential use against Alzheimer's disease, in vitro evaluation of β-amyloid fibril formation using Aβ(1-40) and Aβ(1-42) peptides was performed." | 1.42 | 1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and β-amyloid aggregation inhibitors: biological evaluation and in silico study. ( Ahangar, N; Ahmadnejad, M; Dadashpour, S; Emami, S; Irannejad, H; Ozadali, K; Tuylu Kucukkilinc, T; Unsal Tan, O, 2015) |
| "Indomethacin was the principal metabolite of DP-155 in the serum." | 1.33 | A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar eff ( Angel, I; Dahan, A; Duvdevani, R; Dvir, E; Friedman, JE; Hoffman, A; Koh, JY; Kozak, A; Lee, JY; Raz, S; Rosenberg, G; Shapiro, I; Younis, F, 2006) |
| " These findings indicate that chronic administration of indomethacin by blocking the activation of the NF-kappa B significantly reduces the amyloid pathology in Tg2576 mice, and provide insights into the mechanisms by which this drug could slow progression of AD." | 1.32 | Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. ( Lee, EB; Lee, VM; Praticò, D; Shineman, D; Sung, S; Trojanowski, JQ; Uryu, K; Yang, H; Zhao, L, 2004) |
| "Indomethacin was added in concentrations ranging from 0." | 1.31 | Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect. ( Bollen, EL; Bour, AM; Laterveer, JC; Remarque, EJ; Westendorp, RG, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (25.58) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 8 (18.60) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Stock, N | 1 |
| Munoz, B | 1 |
| Wrigley, JD | 1 |
| Shearman, MS | 1 |
| Beher, D | 1 |
| Peachey, J | 1 |
| Williamson, TL | 1 |
| Bain, G | 1 |
| Chen, W | 1 |
| Jiang, X | 1 |
| St-Jacques, R | 1 |
| Prasit, P | 1 |
| Necula, M | 1 |
| Kayed, R | 1 |
| Milton, S | 1 |
| Glabe, CG | 1 |
| Gökhan-Kelekçi, N | 1 |
| Yabanoğlu, S | 1 |
| Küpeli, E | 1 |
| Salgin, U | 1 |
| Ozgen, O | 1 |
| Uçar, G | 1 |
| Yeşilada, E | 1 |
| Kendi, E | 1 |
| Yeşilada, A | 1 |
| Bilgin, AA | 1 |
| Oehlrich, D | 1 |
| Berthelot, DJ | 1 |
| Gijsen, HJ | 1 |
| Hadjipavlou-Litina, D | 1 |
| Samadi, A | 1 |
| Unzeta, M | 1 |
| Marco-Contelles, J | 1 |
| Irannejad, H | 1 |
| Unsal Tan, O | 1 |
| Ozadali, K | 1 |
| Dadashpour, S | 1 |
| Tuylu Kucukkilinc, T | 1 |
| Ahangar, N | 1 |
| Ahmadnejad, M | 1 |
| Emami, S | 1 |
| Dias, KS | 1 |
| de Paula, CT | 1 |
| Dos Santos, T | 1 |
| Souza, IN | 1 |
| Boni, MS | 1 |
| Guimarães, MJ | 1 |
| da Silva, FM | 1 |
| Castro, NG | 2 |
| Neves, GA | 2 |
| Veloso, CC | 1 |
| Coelho, MM | 1 |
| de Melo, IS | 1 |
| Giusti, FC | 1 |
| Giusti-Paiva, A | 2 |
| da Silva, ML | 1 |
| Dardenne, LE | 2 |
| Guedes, IA | 2 |
| Pruccoli, L | 2 |
| Morroni, F | 1 |
| Tarozzi, A | 2 |
| Viegas, C | 2 |
| Dias Viegas, FP | 1 |
| de Freitas Silva, M | 1 |
| Divino da Rocha, M | 1 |
| Castelli, MR | 1 |
| Riquiel, MM | 1 |
| Machado, RP | 1 |
| Vaz, SM | 1 |
| Simões de Lima, LM | 1 |
| Mancini, KC | 1 |
| Marques de Oliveira, PC | 1 |
| Morais, ÉP | 1 |
| Gontijo, VS | 1 |
| da Silva, FMR | 1 |
| D'Alincourt da Fonseca Peçanha, D | 1 |
| Vilela, FC | 1 |
| Orlandi, L | 1 |
| Camps, I | 1 |
| Veloso, MP | 1 |
| Leomil Coelho, LF | 1 |
| Ionta, M | 1 |
| Ferreira-Silva, GÁ | 1 |
| Pereira, RM | 1 |
| de Oliveira Carneiro Junior, W | 1 |
| Quaglio Bellozi, PM | 1 |
| Pinheiro de Oliveira, AC | 1 |
| Ferreira, FF | 1 |
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 1 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Janockova, J | 1 |
| Soukup, O | 1 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Saudi, MNS | 1 |
| Bartolini, M | 1 |
| Belal, ASF | 1 |
| Zhang, L | 1 |
| Wu, Y | 1 |
| Yang, G | 2 |
| Gan, H | 1 |
| Sang, D | 1 |
| Zhou, J | 1 |
| Su, L | 1 |
| Wang, R | 3 |
| Ma, L | 2 |
| Huang, Y | 1 |
| Huang, W | 1 |
| Karkhah, A | 1 |
| Saadi, M | 1 |
| Pourabdolhossein, F | 1 |
| Saleki, K | 1 |
| Nouri, HR | 1 |
| Jaeger, LB | 1 |
| Dohgu, S | 1 |
| Sultana, R | 1 |
| Lynch, JL | 1 |
| Owen, JB | 1 |
| Erickson, MA | 1 |
| Shah, GN | 1 |
| Price, TO | 1 |
| Fleegal-Demotta, MA | 1 |
| Butterfield, DA | 1 |
| Butterfiled, DA | 1 |
| Banks, WA | 1 |
| Mizushima, T | 1 |
| Bernardi, A | 1 |
| Frozza, RL | 1 |
| Meneghetti, A | 1 |
| Hoppe, JB | 1 |
| Battastini, AM | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Salbego, CG | 1 |
| Casserly, I | 1 |
| Topol, E | 1 |
| Sung, S | 1 |
| Yang, H | 1 |
| Uryu, K | 1 |
| Lee, EB | 1 |
| Zhao, L | 1 |
| Shineman, D | 1 |
| Trojanowski, JQ | 1 |
| Lee, VM | 1 |
| Praticò, D | 2 |
| Lacomblez, L | 1 |
| Ferrera, P | 1 |
| Arias, C | 1 |
| Townsend, KP | 1 |
| Balashov, AM | 1 |
| Dvir, E | 2 |
| Friedman, JE | 2 |
| Lee, JY | 1 |
| Koh, JY | 1 |
| Younis, F | 1 |
| Raz, S | 1 |
| Shapiro, I | 2 |
| Hoffman, A | 2 |
| Dahan, A | 2 |
| Rosenberg, G | 1 |
| Angel, I | 1 |
| Kozak, A | 1 |
| Duvdevani, R | 2 |
| McGeer, PL | 3 |
| Rogers, J | 2 |
| McGeer, EG | 2 |
| Narlawar, R | 1 |
| Pérez Revuelta, BI | 1 |
| Haass, C | 1 |
| Steiner, H | 1 |
| Schmidt, B | 1 |
| Baumann, K | 1 |
| Elman, A | 1 |
| Simmons, D | 1 |
| de Jong, D | 1 |
| Jansen, R | 1 |
| Hoefnagels, W | 1 |
| Jellesma-Eggenkamp, M | 1 |
| Verbeek, M | 1 |
| Borm, G | 1 |
| Kremer, B | 1 |
| Cadman, ED | 1 |
| Witte, DG | 1 |
| Lee, CM | 1 |
| Lockhart, BP | 1 |
| Benicourt, C | 1 |
| Junien, JL | 1 |
| Privat, A | 1 |
| Dal Forno, G | 1 |
| Kawas, CH | 1 |
| Schnabel, J | 1 |
| Kirby, LC | 1 |
| Hempelman, SR | 1 |
| Berry, DL | 1 |
| Kaszniak, AW | 1 |
| Zalinski, J | 1 |
| Cofield, M | 1 |
| Mansukhani, L | 1 |
| Willson, P | 1 |
| Smalheiser, NR | 1 |
| Swanson, DR | 1 |
| Mallet, L | 1 |
| Kuyumjian, J | 1 |
| Rojas-Fernandez, C | 1 |
| Mallery, L | 1 |
| Shen, ZY | 1 |
| Hu, GR | 1 |
| Möller, HJ | 1 |
| Hüll, M | 1 |
| Lieb, K | 1 |
| Fiebich, BL | 1 |
| Ogawa, O | 1 |
| Umegaki, H | 1 |
| Sumi, D | 1 |
| Hayashi, T | 1 |
| Nakamura, A | 1 |
| Thakur, NK | 1 |
| Yoshimura, J | 1 |
| Endo, H | 1 |
| Iguchi, A | 1 |
| Bour, AM | 1 |
| Westendorp, RG | 1 |
| Laterveer, JC | 1 |
| Bollen, EL | 1 |
| Remarque, EJ | 1 |
| Asanuma, M | 1 |
| Nishibayashi-Asanuma, S | 1 |
| Miyazaki, I | 1 |
| Kohno, M | 1 |
| Ogawa, N | 1 |
| Weggen, S | 1 |
| Eriksen, JL | 1 |
| Das, P | 1 |
| Sagi, SA | 1 |
| Pietrzik, CU | 1 |
| Findlay, KA | 1 |
| Smith, TE | 1 |
| Murphy, MP | 1 |
| Bulter, T | 1 |
| Kang, DE | 1 |
| Marquez-Sterling, N | 1 |
| Golde, TE | 1 |
| Koo, EH | 1 |
| Tabet, N | 1 |
| Feldman, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peripheral Markers of Inflammation in Patients With Alzheimer's Disease Compared to Cognitively Normal Elderly[NCT02472899] | 115 participants (Actual) | Observational | 2007-02-28 | Completed | |||
| Effect of Indomethacin on the Progression of Alzheimer's Disease[NCT00432081] | Phase 3 | 160 participants | Interventional | 2000-05-31 | Completed | ||
| Biomarkers of Nonsteroidal Anti-Inflammatories[NCT00239746] | Phase 1 | 40 participants (Anticipated) | Interventional | 2005-10-31 | Active, not recruiting | ||
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for indomethacin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Ant | 2011 |
[Novel pharmacological effects of NSAIDs and their molecular mechanism].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2012 |
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cholest | 2004 |
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Animals, Genetically Modified; Anti-Inflammator | 2005 |
[Non-steroid anti-inflammatory drugs in the treatment of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Indome | 2005 |
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Anti-Inflammatory Agents, Non-Steroidal; C-Reacti | 2006 |
DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy.
Topics: Alzheimer Disease; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; D | 2007 |
Cognitive problems in the elderly.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Dementia; Humans; Indomethacin; Mental Recall; Neurops | 1995 |
Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Complemen | 1998 |
[Progress in the pathogenic studies of Alzheimer's disease and its therapeutic approach].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomethacin; Medicine, Chinese | 1996 |
Therapeutic strategies based on immunological hypotheses of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Controlled Clinical Trials as Topi | 1998 |
Anti-inflammatory drugs: a hope for Alzheimer's disease?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclooxygenase 2; Cyclooxygenase | 2000 |
Indomethacin for the treatment of Alzheimer's disease patients.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomethacin | 2002 |
2 trials available for indomethacin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Double-Blind Method | 2008 |
Clinical trial of indomethacin in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Double-Blind Method; Female; Humans; Indomethacin; Male; Neuropsychological | 1993 |
28 other studies available for indomethacin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2006 |
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Humans; Plaque, Amyloid; Protein Structu | 2007 |
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
Topics: Alzheimer Disease; Analgesics; Animals; Anti-Inflammatory Agents; Edema; Hindlimb; Hydrogen Bonding; | 2007 |
Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives.
Topics: Alzheimer Disease; Animals; Antioxidants; Biocatalysis; Biphenyl Compounds; Carrageenan; Edema; Fema | 2013 |
1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and β-amyloid aggregation inhibitors: biological evaluation and in silico study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cyclooxygenase 1; Cyclo | 2015 |
Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease.
Topics: Acrylates; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cells, Cul | 2017 |
Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.
Topics: Acetylcholinesterase; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inh | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Coumarins; Drug Design; Humans; Molecular Docking Simulati | 2020 |
Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents.
Topics: Alzheimer Disease; Animals; Cell Line; Diosgenin; Dose-Response Relationship, Drug; Drug Design; Inf | 2021 |
Indomethacin attenuates neuroinflammation and memory impairment in an STZ-induced model of Alzheimer's like disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Indomethacin; Male; Memory Diso | 2021 |
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Blotting, Western; Brain; Cy | 2009 |
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease | 2012 |
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2004 |
[Inflammation, nonsteroidal anti-inflammatory drugs and Alzheimer disease].
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxy | 2004 |
Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Cell Line, | 2005 |
A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar eff
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Area Under Curve; Brain; Brain Chemistry; Dinopro | 2006 |
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anti-Inflammatory Ag | 2006 |
Regulation of the release of interleukin-6 from human astrocytoma cells.
Topics: Adenylyl Cyclases; Alzheimer Disease; Astrocytoma; Calcium; Cycloheximide; Dinoprostone; Enzyme-Link | 1994 |
Inhibitors of free radical formation fail to attenuate direct beta-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures.
Topics: Allopurinol; Alzheimer Disease; Amino Acid Oxidoreductases; Amyloid beta-Peptides; Animals; Arginine | 1994 |
New Alzheimer's therapy suggested.
Topics: Alzheimer Disease; Amyloid; Anti-Inflammatory Agents, Non-Steroidal; Brain; Humans; Indomethacin; In | 1993 |
Indomethacin and Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Databases, Bibliographic; Humans; Indome | 1996 |
Indomethacin-induced behavioral changes in an elderly patient with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Gout; Gout Suppressants; Humans; Indomethacin; Male; Psy | 1998 |
Indomethacin is inappropriate for use in the geriatric population.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomet | 1998 |
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antineoplastic Agents; Cell Line; Cyclooxygenase | 2000 |
Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cytokines; Dinoprostone; Female; Humans; In Vitro | 2000 |
Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzoates; Cell Death; | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2001 |